ISSUE 95 I June 2020

A cure

for a cost

Who foots the bill for vaccines and treatments developed during a pandemic?

Where are the whistleblowers?

Creating a pharma playbook

2020: The year of the spin out?

02/24/2024 02:42:33

05/27/2020 00:00:00

Go to article: Home | A cure for a cost Go to article: In this issue Go to article: SHL Group Company Insight Go to article: Scandinavian Health Go to article: Contents Go to article: News Go to article: NSF Go to article: VEGA Company Insight Go to article: VEGA Australia Go to article: Covid-19 executive briefing by GlobalData Go to article: The value of real-world evidence during the Covid-19 outbreak Go to article: Covid-19: UK restricts parallel export of nearly 200 drugs, threatening its biopharma industry Go to article: Pharmaceutical professionals say employee safety and supply chain disruption are top Covid-19 concerns Go to article: AbbVie’s, Ascletis’ protease inhibitors spark skeptical outlook for repurposed activity in Covid-19 Go to article: Phoenix Go to article: Phoenix Company Insight Go to article: The pharma industry briefing Go to article: No time to waste: repurposing drugs to tackle covid-19 Go to article: How safe are simple painkillers?Go to article: Molnar Company Insight Go to article: Molnar-Institute Go to article: Modelling the human body: a game changer for drug testing?Go to article: Pandemic pricing: existing drugs and price gouging Go to article: Contract Pharmaceuticals Limited Canada Go to article: Pandemic pricing: novel treatments and vaccines Go to article: The dark side of anticoagulants: will a new approach shed light?Go to article: Zenatek Go to article: Finding a cure for HIV with ViiV Healthcare and UNC-Chapel Hill Go to article: Disputing the facts: is the legal battle between Veeva and IQVIA an antitrust issue Go to article: Nelson Labs Go to article: Could nanoparticles unlock the pharmaceutical benefits of turmeric?Go to article: Why aren’t more companies automating PV data capture?Go to article: Modality Solutions Go to article: Deals in brief powered by GlobalData Go to article: The key list powered by GlobalData Go to article: Butterworth Go to article: Global markets and indices powered by GlobalData Go to article: Macro-economic indicators (1 of 2) powered by GlobalData Go to article: Macro-economic indicators (2 of 2) powered by GlobalData Go to article: Mimotopes Go to article: Events Go to article: Next issue